PetVivo Holdings Inc
OTC:PETV
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
PetVivo Holdings Inc
OTC:PETV
|
25.8m USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
201.9B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
178.4B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
148B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
125B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
113.6B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
46.4B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
52.6B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
50.3B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
50.3B USD |
Loading...
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
38.3B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
PetVivo Holdings Inc
Glance View
PetVivo Holdings, Inc. is a veterinary biotech and biomedical device company. The company is headquartered in Edina, Minnesota. The company went IPO on 2012-07-10. The firm is primarily engaged in the business of translating or adapting human biotech and medical technology into products for commercialization in the veterinary market to treat companion animals such as dogs, horses, cats, and other animals suffering from osteoarthritis and other afflictions. The Company’s pipeline product, Kush, is comprised of a patented, gel-like, protein-based biomaterial which may be injected into the afflicted body parts of companion animals suffering from osteoarthritis. Kush’s predecessor formulation completed a Gel-Del-sponsored 145 patient First-in-Man IDE clinical trial using the novel thermoplastic biomaterial as dermal filler for human cosmetic applications.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for PetVivo Holdings Inc is 66%, which is below its 3-year median of 71.4%.
Over the last 3 years, PetVivo Holdings Inc’s Gross Margin has increased from 40% to 66%. During this period, it reached a low of 40% on Dec 31, 2022 and a high of 108.5% on Dec 31, 2024.
